BARCELONA – According to an innovative study, patients with first-line EGFR-mutated non-small cell lung cancer (NSCLC) can avoid acquired resistance more effectively with a novel combination therapy consisting of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE® (lazertinib) than with osimertinib, the current standard of care. Patients suffering from this prevalent type of lung cancer now have new hope because to the results of the Phase 3 MARIPOSA research, which were presented at the International Association for the Research of Lung Cancer (IASLC) 2025 World Congress.
The trial, which included 1,074 patients, showed that RYBREVANT® and LAZCLUZE® together not only increase longevity but also dramatically lower the emergence of treatment resistance, which is a significant obstacle in the management of non-small cell lung cancer. This is a significant development because resistance mutations eventually cause the disease to worsen in many patients receiving third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib.
Read More: STELARA® (ustekinumab) for Pediatric Crohn’s Disease: Johnson & Johnson Files for FDA Approval
According to the latest research, the combination of RYBREVANT® and LAZCLUZE® efficiently lowers the incidence of frequent resistance mutations in both EGFR and MET, two important pathways in the development of lung cancer. It is thought that this dual-action strategy is what led to the better study results.
We now have a body of evidence that suggests TKI monotherapy is no longer enough in the first-line treatment of EGFR-mutated lung cancer.
The MARIPOSA results show that combining RYBREVANT with LAZCLUZE is an important step forward, reducing EGFR- and MET-driven resistance seen with TKI-based therapy and giving patients a longer, stronger first response.
Sanjay Popat
Read More: Johnson & Johnson Discontinued VENTURA Drug Development Program
No new safety issues were discovered, and the safety profile of the RYBREVANT® and LAZCLUZE® combination was determined to be in line with earlier findings. By taking preventative steps, common adverse effects such as skin responses and infusion-related reactions could be controlled.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
About RYBREVANT® and LAZCLUZE®
LAZCLUZE® (lazertinib) is a third-generation EGFR TKI, while RYBREVANT® (amivantamab-vmjw) is a bispecific antibody that targets both the EGFR and MET pathways. Several markets have approved this combination medication for the treatment of specific NSCLC types.
About Non-Small Cell Lung Cancer (NSCLC)
The most prevalent kind of lung cancer is non-small cell lung cancer (NSCLC), and EGFR mutations are frequently the cause of the illness. Even though EGFR TKIs have completely changed how this cancer is treated, acquired resistance is still a major obstacle. According to the results of the MARIPOSA research, patients may have a greater probability of long-term disease control if this novel combination therapy is adopted as the new standard of care for the first-line treatment of EGFR-mutated NSCLC.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
